Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Agenebio Inc.

Headquarters: Baltimore, MD, United States of America
Year Founded: 2008
Status: Private

BioCentury | Feb 14, 2023
Management Tracks

J&J hires Sanofi’s Reed

Plus: Roth named COO at Zentalis and updates from Treeline, SpyBiotech and Life
BioCentury | Mar 1, 2022
Deals

VCs gain exit as AbbVie buys UCB neuro spinout Syndesi

With Syndesi takeout, AbbVie gains clinical molecule designed to improve cognitive function
BioCentury | Jul 3, 2018
Company News

Management tracks: Cigna, Novocure, Voyager

BioCentury | Mar 29, 2018
Emerging Company Profile

Strengthening synapses

How Syndesi’s SV2A modulators may restore function to more synapses in AD
BioCentury | Apr 6, 2015
Clinical News

Levetiracetam: Phase II data

BioCentury | Jul 28, 2014
Company News

AgeneBio board of directors update

BioCentury | Jul 28, 2014
Company News

AgeneBio management update

BioCentury | May 24, 2012
Targets & Mechanisms

Cooling down AD

BioCentury | May 24, 2012
Distillery Therapeutics

Indication: Neurology

BioCentury | May 31, 2010
Financial News

AgeneBio completes venture financing

Items per page:
1 - 10 of 10